Haemostasis · 2009 · 15 citations · 0 references
MedicineHematologyPharmacotherapyHemostasisImmunopharmacologyTransfusion MedicineBleeding DisordersCoagulation DisordersHemostatic AgentsThrombosisThrombotic DisordersVon Willebrand DiseaseBleedingBleeding Time AssessmentBleeding Time PhysiologyFactor Viii ActivationFactor Viii AlterationsFactor Viii PhysiologyVon Willebrand Factor Activity AssaysVon Willebrand Factor Function
5 patients suffering from von Willebrand's syndrome were treated with DDAVP administered intravenously or intransally. The concentration of F. VIII-related activities (F. VIII:C, F. VIII R:AG, F. VIII R:WF), as well as the mobility of F. VIII R:AG in crossed immunoelectrophoresis and the alterations of bleeding time were continuously monitored. DDAVP induced both quantitative and qualitative changes of F. VIII-related properties. The bledding time was markedly reduced for some hours. The therapy was well tolerated and should be submitted to further clinical trials as a possible way to avoid the disadvantages connected with the transfusion of blood components.